GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Silk Road Medical Inc (NAS:SILK) » Definitions » Financial Strength

Silk Road Medical (Silk Road Medical) Financial Strength

: 6 (As of Dec. 2023)
View and export this data going back to 2019. Start your Free Trial

Silk Road Medical has the Financial Strength Rank of 6.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Silk Road Medical did not have earnings to cover the interest expense. Silk Road Medical's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.41. As of today, Silk Road Medical's Altman Z-Score is 2.65.


Competitive Comparison

For the Medical Devices subindustry, Silk Road Medical's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silk Road Medical Financial Strength Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's Financial Strength distribution charts can be found below:

* The bar in red indicates where Silk Road Medical's Financial Strength falls into.



Silk Road Medical Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Silk Road Medical's Interest Expense for the months ended in Dec. 2023 was $-1.7 Mil. Its Operating Income for the months ended in Dec. 2023 was $-14.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $75.6 Mil.

Silk Road Medical's Interest Coverage for the quarter that ended in Dec. 2023 is

Silk Road Medical did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Silk Road Medical's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.703 + 75.626) / 189.08
=0.41

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Silk Road Medical has a Z-score of 2.65, indicating it is in Grey Zones. This implies that Silk Road Medical is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.

Warning Sign:

Altman Z-score of 2.65 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Silk Road Medical  (NAS:SILK) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Silk Road Medical has the Financial Strength Rank of 6.


Silk Road Medical Financial Strength Related Terms

Thank you for viewing the detailed overview of Silk Road Medical's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Silk Road Medical (Silk Road Medical) Business Description

Traded in Other Exchanges
Address
1213 Innsbruck Drive, Sunnyvale, CA, USA, 94089
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
Executives
Chas Mckhann director, officer: Chief Executive Officer 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Marie L. Jones officer: CAO and VP, Finance 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Lucas W. Buchanan officer: Chief Financial Officer C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Kevin M Klemz officer: EVP/Chief Legal Officer/Sec. 9600 54TH AVENUE NORTH, SUITE 100, PLYMOUTH MN 55442
Andrew S. Davis officer: Chief Commercial Officer C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Erica J. Rogers director, officer: President and CEO C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Elizabeth H Weatherman director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Richard Ruedy officer: EVP Clin & Reg. Affairs and QA C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Tony M. Chou director C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Tanisha Carino director C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Kevin J. Ballinger director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Rick D Anderson director 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746
Donald Zurbay director C/O ST. JUDE MEDICAL, INC., ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
Warburg Pincus Partners Gp Llc 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus & Co. 10 percent owner 450 LEXINGTON AVENUE, NEW YORK, NY NY 100173147